Category: Leadership 3

Jeff Goater

Jeff Goater joined The Column Group as a Venture Partner in 2021. Previously, he served as Chief Executive Officer of Surface Oncology.  During his tenure at Surface, the company fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline.  …

Jeff Goater Read More »

Sarah Hymowitz, PhD

Dr. Hymowitz joined The Column Group in 2021 as a Venture Partner.  Previously, she spent 22 years at Genentech rising to Vice President of Protein Sciences. In this role, she oversaw the large molecule drug discovery portfolio and mentored project teams on the identification and optimization of more than 35 clinical candidates. Earlier, as a …

Sarah Hymowitz, PhD Read More »

John Josey

John Josey, PhD

Dr. Josey joined The Column Group as a Venture Partner in 2020. Previously he served as the President, Chief Executive Officer and a member of the Board of Directors of Peloton Therapeutics, Inc., from 2013 until its acquisition by Merck in 2019. He joined Peloton in 2011 as the first employee in the role of …

John Josey, PhD Read More »

JJ Kang

JJ Kang, PhD

Dr. Kang joined The Column Group in 2015. Previously, Dr. Kang worked at FibroGen in the project management of drug discovery and development programs, and prior to that, in corporate strategy. Dr. Kang investigated inhibition of DNA methylation and chemical induction of immunogenicity in cancer cells in the laboratory of Professor Peter Dervan, completing her …

JJ Kang, PhD Read More »

Scroll to Top